Acute Myelogenous Leukemia (AML) Clinical Trial
Official title:
A Phase I Trial of MAX-40279 Given Orally to Subjects With Acute Myelogenous Leukemia (AML)
This is a dose-escalation phase I trial to evaluate the safety and tolerability of MAX-40279 in subjects with acute myelogenous leukemia(AML).
Status | Recruiting |
Enrollment | 30 |
Est. completion date | December 1, 2022 |
Est. primary completion date | November 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Males and/or females over age 18 2. Ability to understand the purposes and risks of the trial and signed informed consent forms approved by the investigator's Institutional Review Board (IRB)/Independent Ethics Committee (IEC) of the trial site was obtained before the entering the trial 3. Subject has morphologically documented primary AML or AML secondary to myelodysplastic syndrome (MDS) as defined by the World Health Organization (WHO) criteria for which no established standard therapy is available 4. ECOG performance status of 0 to 2 5. Persistent chronic clinically significant nonhematological toxicities from prior treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation, HSCT, or surgery) must be Grade = 1 6. In the absence of rapidly progressing disease clearly documented by the investigator, the interval from prior treatment to time of MAX-40279 administration will be at least 2 weeks (14 days) for prior cytotoxic agents or at least 5 half-lives for prior noncytotoxic agents, including immunosuppressive therapy post HSCT 7. Acceptable liver function defined below: - Total bilirubin = 1.5 times upper limit of normal range (ULN) - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3 times ULN; 8. Acceptable renal function defined below: • Serum creatinine = 1.5 times ULN or calculated creatinine clearance (by the Cockcroft-Gault formula) = 60 mL/min 9. Acceptable coagulation status defined below: - Prothrombin time < 1.3 times ULN - Partial thrombin time < 1.3 times ULN 10. No clinically significant abnormalities in urinalysis 11. Female participants of child bearing potential agree not to be pregnant or lactating during the study and for three months following the last dose of study drug. Both men and women of reproductive potential must agree to use a highly effective method of birth control during the study and for three months following the last dose of study drug. A highly effective method of contraception is defined as one that results in a low failure rate, i.e., less than 1% per year, when used consistently and correctly Exclusion Criteria: 1. Disease diagnosis of acute promyelocytic leukemia 2. Previously treated malignancies other than the current disease, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years at the trial entry 3. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy 4. Major surgery, other than diagnostic surgery, within 4 weeks prior to the trial entry, without complete recovery 5. Percutaneous coronary intervention conducted within 6 months prior to the trial entry for cardiac infarction or angina pectoris 6. Seizure disorders requiring anticonvulsant therapy 7. Taking a medication that prolongs QT interval and has a risk of Torsades de Pointes,or a history of long QT syndrome 8. Medical history of difficulty swallowing, malabsorption or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested product 9. Participation in an investigational drug or device trial within 4 weeks prior to the trial entry 10. Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C 11. Recent venous thrombosis (including deep vein thrombosis or pulmonary embolism within 1 year of study) 12. History of upper gastrointestinal hemorrhage, peptic ulcer disease, or bleeding diathesis 13. Subject is pregnant (positive serum beta human chorionic gonadotropin [ß-HCG] test at screening) or is currently breast-feeding, their partner anticipates becoming pregnant/impregnating during the trial or within 6 months after receiving the last dose of trial treatment 14. Concomitant disease or condition that could interfere with the conduct of the trial, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this trial 15. Unwillingness or inability to comply with the trial protocol for any reason 16. Legal incapacity or limited legal capacity 17. Cardiac disease with New York Heart Association (NYHA) Class III or IV, including congestive heart failure, myocardial infarction within 6 months prior to the trial entry, unstable arrhythmia, or symptomatic peripheral arterial vascular |
Country | Name | City | State |
---|---|---|---|
Australia | Monash Health | Clayton | Victoria |
Australia | St Vincent's Hospital Sydney Limited | Darlinghurst | New South Wales |
Australia | Western NSW Local Health District | Dubbo | New South Wales |
Australia | Austin Health | Heidelberg | Victoria |
Lead Sponsor | Collaborator |
---|---|
Maxinovel Pty., Ltd. |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adverse events (AEs) | Incidence of treatment-related AEs | 8 weeks | |
Primary | Maximum tolerated dose (MTD) | MTD will be defined as the maximum dose level at which no more than 1 of 3 participants experience a dose-limiting toxicity (DLT) within the first 4 weeks of multiple dosing. | 4 weeks | |
Secondary | Tmax | Time to maximum plasma concentration | First single dose(pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24h post-dose), Cycle 1 Day 1 (the second dose)(pre-dose),Cycle 1 Day 15(pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24h post-dose), Cycle 1 Day 28(pre-dose), Cycle 2 Day 28(pre-dose). | |
Secondary | Cmax | Maximum plasma drug concentration | First single dose(pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24h post-dose), Cycle 1 Day 1 (the second dose)(pre-dose),Cycle 1 Day 15(pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24h post-dose), Cycle 1 Day 28(pre-dose), Cycle 2 Day 28(pre-dose). | |
Secondary | AUC | Area under the time-concentration curve | First single dose(pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24h post-dose), Cycle 1 Day 1 (the second dose)(pre-dose),Cycle 1 Day 15(pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24h post-dose), Cycle 1 Day 28(pre-dose), Cycle 2 Day 28(pre-dose). | |
Secondary | t1/2 | Observed terminal half-life | First single dose(pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24h post-dose), Cycle 1 Day 1 (the second dose)(pre-dose),Cycle 1 Day 15(pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24h post-dose), Cycle 1 Day 28(pre-dose), Cycle 2 Day 28(pre-dose). | |
Secondary | p-FLT3 Y591 | To examine the phosphorylation (activation) of either wild-type or mutated Fms-like Tyrosine Kinase-3(FLT3) | First single dose(pre-dose), Cycle 1 Day 15(pre-dose), Cycle 1 Day 28(pre-dose), Cycle 2 Day 28(pre-dose). | |
Secondary | FGFR aberration | To detect Fibroblast growth factor receptor(FGFR) mutation | First single dose(pre-dose), Cycle 1 Day 15(pre-dose), Cycle 1 Day 28(pre-dose), Cycle 2 Day 28(pre-dose). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00528983 -
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
|
Phase 1 | |
Completed |
NCT01221857 -
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
|
Phase 1/Phase 2 | |
Terminated |
NCT01451437 -
Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649)
|
Phase 1 | |
Completed |
NCT01885897 -
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
|
Phase 1/Phase 2 | |
Recruiting |
NCT05884333 -
Cord Blood Transplant in Adults With Blood Cancers
|
Phase 2 | |
Terminated |
NCT01873495 -
Omacetaxine for Consolidation and Maintenance
|
Phase 2 | |
Terminated |
NCT03600909 -
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
|
Phase 2 | |
Completed |
NCT00088543 -
Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant
|
N/A | |
Active, not recruiting |
NCT02061800 -
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
|
Phase 1/Phase 2 | |
Terminated |
NCT01113502 -
Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00943553 -
A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects
|
Phase 2 | |
Terminated |
NCT01050764 -
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
|
Phase 1/Phase 2 | |
Terminated |
NCT00672152 -
A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation
|
Phase 1 | |
Recruiting |
NCT03260101 -
Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study
|
||
Terminated |
NCT02200380 -
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
|
Phase 2 | |
Active, not recruiting |
NCT02240537 -
Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer
|
Phase 1 | |
Completed |
NCT01527838 -
Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit
|
Phase 1 | |
Terminated |
NCT00779480 -
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)
|
Phase 1 | |
Completed |
NCT01768845 -
Unrelated Umbilical Cord Blood (UBC)Transplantation
|
N/A | |
Terminated |
NCT01265199 -
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
|
Phase 1 |